Cancer heterogeneity and "The struggle for existence": Diagnostic and analytical challenges

Cancer Letters

Volumn 340, Issue 2, 2013, Pages 220-226

  Horswell, Stuart ^a   Matthews, Nicholas ^a   Swanton, Charles ^a,b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Bioinformatics; Cancer heterogeneity; Drug resistance; Next generation sequencing

Indexed keywords

BCR ABL PROTEIN; IMATINIB; LAPATINIB;

BIOINFORMATICS; BREAST CANCER; BREAST CARCINOMA; CANCER GENETICS; CANCER GROWTH; CANCER STAGING; CELL FREE SYSTEM; CHRONIC MYELOID LEUKEMIA; CLEAR CELL CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; CONVERGENT EVOLUTION; DRUG BINDING; GENETIC DIFFERENCE; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HUMAN; KARYOTYPE; LUNG NON SMALL CELL CANCER; MICROSATELLITE MARKER; NEOPLASM; PANCREAS CANCER; POINT MUTATION; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

EID: 84887609665     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.10.031     Document Type: Review

References (46)

1. M. Turner, E. coli outbreak strain in genome race, Nature. doi:10.1038/news.2011.430.
2. Topol E. The Creative Destruction of Medicine 2012, Basic Books, New York.
3. Fisher B., Redmond C., Fisher E. Evolution of knowledge related to breast cancer heterogeneity: a 25 - year retrospective. J. Clin. Oncol. 2008, 26:2068-2071.
4. Halvorsen T., Seim E. Degree of differentiation in colorectal adenocarcinomas: a multivariate analysis of the influence on survival. J. Clin. Pathol. 1988, 41:532-537.
5. Hultborn K.A. Cancer of the colon and rectum: a clinical and pathological study with special reference to the possibilities of improving the diagnostic methods and the therapeutic results in adenocarcinoma. Acta Chir. Scand. 1952, 172(suppl.):62-77.
6. Nowell P. The clonal evolution of tumour cell populations. Sci., New Ser., Col. 1976, 194(4260):23-28.
7. Teixeira M.R., Pandis N., Bardi G., Andersen J.A., Heim S. Karyotypic comparisons of multiple tumorous and macroscopically normal surrounding tissue samples from patients with breast cancer. Cancer Res. 1996, 56:855-859.
8. Aubele M., Mattis A., Zitzelsberger H., Walch A., Kremer M., Hutzler P., et al. Intratumoral heterogeneity in breast carcinoma revealed by laser-microdissection and comparative genomic hybridization. Cancer Genet. Cytogenet. 1999, 110:94-102.
9. Khalique L., Ayhan A., Weale M.E., Jacobs I., Ramus S.J., Gayther S.A. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J. Pathol. 2007, 211:286-295.
10. Thirlwell C., Will O.C.C., Domingo E., Graham T.A., McDonald S.A.C., Oukrif D., et al. Clonality assessment and clonal ordering of individual neoplastic crypts shows polyclonality of colorectal adenoma. Gastroenterology 2010, 138:1441-1454.
11. Reid B.J., Prevo L.J., Galipeau P.C., Sanchez C.A., Longton G., Levine D.S., et al. Predictors of progression in Barrett's Esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am. J. Gasteroenterol. 2001, 96:2839-2848.
12. Maley C.C., Galipeau P.C., Finley J.C., Wongsurawat V.J., Li X., Sanchez C.A., et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 2006, 34:468-473.
13. Anderson K., Lutz C., van Delft F.W., Bateman C.M., Guo Y., Colman S.M., et al. Genetic variegation of clonal architecture and propogating cells in leukaemia. Nature 2011, 469:356-361.
14. Campbell P., Yachida S., Mudie L.J., Stephens P.J., Pleasance E.D., Stebbings A., et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010, 467:1109-1113.
15. Yachida S., Jones S., Bozic I., Antal T., Leary R., Fu B., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
16. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endersfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Eng. J. Med. 2012, 366:883-892.
17. Navin N., Krasnitz A., Rodgers L., Cook K., Meth J., Kendall J., et al. Inferring tumor progression from genomic heterogeneity. Genome Res. 2010, 20:68-80.
18. Shah S.P., Morin R.D., Khattra J., Prentice L., Pugh T., Burleigh A., et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813.
19. Shah S.P., Roth A., Goya R., Oloumi A., Ha G., Zhao Y., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
20. Nik-Zainal S., van Loo P., Wedge D.C., Alexandrov L.B., Greenman C.D., Lau K.W., et al. Breast cancer working group of the international cancer genome consortium, the life history of 21 breast cancers. Cell 2012, 149:994-1007.
21. Walter M.J., Shen D., Dig L., Shao J., Koboldt D.C., Chen K., et al. Clonal architecture of secondary acute myeloid leukemia. N. Eng. J. Med. 2012, 366:1090-1098.
22. Zhang J., Ding L., Holmfeldt L., Wu G., Heatley S.L., Payne-Turner D., et al. The genetic basis of early T-Cell precursor acute lymphoblastic leukaemia. Nature 2012, 481:157-163.
23. Turke A.B., Zejnullahu K., Wu Y.-L., Song Y., Dias-Santagata D., Lifshits E., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
24. Su K.-Y., Chen H.-Y., Li K.-C., Kuo M.-L., Yang J.C.-H., Cham W.-K., et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinas inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 2012, 30:433-440.
25. Willis S.G., Lange T., Demehir S., Otto S., Crossman L., Niederwieser D., et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005, 106:2128-2137.
26. Wardlemann E., Thomas N., Merkelbach-Bruse S., Pauls K., Speidel N., Buttner R., et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 2005, 6:249-251.
27. Wardelmann E., Merkelbach-Bruse S., Pauls K., Thomas N., Schildhaus H.-U., Heinicke T., et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumours under treatmen with imatinib mesylate. Clin. Cancer Res. 2006, 12:1743-1749.
28. Forshew T., Murtza M., Parkinson C., Gale D., Tsui D.W.Y., Kaper F., et al. Sci. Transl. Med. 2012, 4. (36ra68).
29. Kelly R.J., Carter C.A., Giaccone G. HER2 mutations in non-small-cell lung cancer can be continually targeted. J. Clin. Oncol. 2012, 30:3318-3319.
30. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Nat. Acad. Sci. 2001, 98:5116-5121.
31. Smyth G.K. Limma: linear models for microarray data. Bioinformatics and Computational Biology solutions using R and Bioconductor 2005, 397-420. Springer, New York. R. Gentleman, V. Carey, S. Dudoit, R. Irizarry, W. Huber (Eds.).
32. http://www.oxfordjournals.org/our_journals/bioinformatics/nextgenerationsequencing.html (retrieved 31.08.12).
33. Roth A., Morin R., Ding J., Crisan A., Ha G., Giuliany R., et al. JointSNVMix: a probabilistic model for accurate detectionof somatic mutations in normal/tumour paired next generation sequencing data. Bioinformatics 2012, 28:907-913.
34. Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011, 469:539-542.
35. 1000 Genomes Project Consortium A map of human genome variation from population-scale sequencing. Nature 2010, 467:1061-1073.
36. Merlo L.M.F., Shah N.A., Li X., Blount P.L., Vaughn T.L., Reid B.J., et al. A comprehensive survey of clonal diversity measures in barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev. Res. 2010, 3:1388-1397.
37. Shannon C.E. A mathematical theory of communication. Bell Syst. Tech. J. 1948, 27:379-423. 623-656.
38. Berger M.F., Lawrence M.S., Demichelis F., Drier Y., Cibulskis K., Sivachenko A.Y., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
39. Koren S., Schatz M.C., Walenz B.P., Martin J., Howard J.T., Ganapathy G., et al. Hybrid error correction and de novo assembly of single molecule sequencing reads. Nat. Biotechnol. 2012, 30:693-700.
40. E.C. Hayden, Nanopore genome sequencer makes its debut. Nature. doi:10.1038/nature.2012.10051.
41. Cherf G.M., Lieberman K.R., Rashid H., Lam C.E., Karplus K., Akeson M. Automated forward and reverse ratcheting of DNA in a nanopore at 5-A precision. Nat. Biotechnol. 2012, 30:344-348.
42. Poste G. Bring on the biomarkers. Nature 2011, 469:156-157.
43. Lee A.J.X., Endersfelder D., Rowan A.J., Walther A., Birkbak N.J., Futreal P.A., et al. Chromosomal instability conferred intrinsic multidrug resistance. Cancer Res. 2011, 71:1858-1870.
44. Edgar R., Domrachev M., Lash A.E. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002, 30:207-210. http://www.ncbi.nlm.nih.gov/geo/.
45. http://www.ncbi.nlm.nih.gov/sra.
46. http://sagebase.org/.